Kanecia Obie Zimmerman
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Kanecia Obie Zimmerman sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Kanecia Obie Zimmerman: 7 sponsored US clinical trials, none currently recruiting.
Kanecia Obie Zimmerman sponsors 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Long Coronavirus Disease 2019 (Covid19), with 1 trials.
Upper-quartile sponsor footprint
Kanecia Obie Zimmerman sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
7 total, page 1 of 1
RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)
NCT06305793
RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine)
NCT06305806
RECOVER-AUTONOMIC Platform Protocol
NCT06305780
Single Dose IV Methadone for Post-Op Pain
NCT05425420
RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms
NCT05595369
RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms
NCT05965726
Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH)
NCT02913612
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 6 |
Therapeutic Areas
How the Kanecia Obie Zimmerman early-phase archive is shaped
7 indexed studies, none listed as recruiting (0% open); 6 completed (86%).
Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).
Top condition: Long Coronavirus Disease 2019 (Covid19) (1 trial), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Kanecia Obie Zimmerman: archived-pipeline peers nationwide
Peers matched on 7 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Kanecia Obie Zimmerman sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 archived trials
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Kanecia Obie Zimmerman page
7 registered trials is a research-attention snapshot, not an endorsement of Kanecia Obie Zimmerman or any single study.
- None of Kanecia Obie Zimmerman's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Long Coronavirus Disease 2019 (Covid19) is the condition Kanecia Obie Zimmerman studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Long Coronavirus Disease 2019 (Covid19) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Kanecia Obie Zimmerman pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.